Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA is pushing new guidelines for cancer trials, recommending overall survival as a primary endpoint. Capricor Therapeutics is asking the FDA to reconsider their rejection of a treatment for DMD cardiomyopathy with the return of Vinay Prasad. Rocket Pharmaceuticals' phase II trial has resumed after a patient death, and the Trump administration's tariffs and drug pricing policies are causing confusion in the pharmaceutical industry. Fedegari is now offering customized solutions for the bio/pharmaceutical industry. The American Academy of Pediatrics is recommending the COVID-19 vaccine for kids, and there are updates on various biotech developments. Opinion pieces discuss drug pricing and the viability of high-dose peptides.The American pharmaceutical industry has lost the trust of the people, with many viewing them as the 'bad guys' despite producing drugs in the U.S. for Americans. The industry faces challenges such as competition and changing regulations, with the Trump administration's trade policies adding to the confusion. Some companies are taking a platform strategy approach to drug development, using one molecule to target multiple diseases. Despite these challenges, there are opportunities for innovation and growth in the industry. Additionally, conflicts of interest in vaccine committees have been decreasing, and companies are making strategic moves such as forming partnerships and restructuring to adapt to the changing landscape. The industry continues to navigate uncertainty and seek ways to improve drug development and access for patients.

Support the show